John Noseworthy

Chasing Cures: Reinventing the Business of Medicine

Melissa Stevens, John Noseworthy, Francis Collins, Mark Rothera, Melinda Richter, Monsef Slaoui

A panel of industry leaders and NIH officials advocates transforming biomedical research through open innovation models like the Accelerating Medicines Partnership, which pools $30 billion in funding to address major diseases by sharing data across pre-competitive collaborations. The discussion highlights a strategic shift toward patient-centric trials using real-world evidence and wearable technology to accelerate discovery while redefining value to include safety and patient-defined outcomes over mere cost containment. Looking ahead, experts anticipate breakthroughs in bio-electronic medicine and precision therapies, driven by regulatory reforms for orphan drugs and non-traditional partnerships that prioritize patient access over traditional discovery-to-commercialization silos.